FinanceFinancial Postabout 3 hours ago
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
1 min read
Biogen agreed to acquire RayThera Inc. for up to $1 billion, adding multiple anti-inflammatory assets to its immunology pipeline. The lead candidate is expected to enter Phase 1 development in early Q3 2026. The deal includes an upfront payment and milestone-contingent payments.
Level
Hype check
Tap to vote and see what everyone thinks.
